Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06731842

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

Multi-modal PET tracer study with the aim of studying the time course of regional deposition of tau in brain of subjects with high risk of being carriers of autosomal dominant Alzheimer´s disease and sporadic early onset and late onset Alzheimer´s disease patient (EOAD, LOAD) in tertiary memory clinic cohort in relation to MRI brain changes, plasma biomarker levels and cognitive performance.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Alzheimer´s Disease

Age range

30 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Karolinska institutet NVS

Stockholm, 141 52, Sweden

About this study

Multi-PET /MRI studies , fluid biomarkers (CSF, plasma) analysis, neuropsychological testing is performed in subjects carriers and non-carriers of different APP, PS autosomal dominant AD mutatation. Both presymptomatic and symptomatic carriers and non-carriers are recruited (age range -30 to +15 years from first clinical symptoms). For comparison also a group of healthy eldersly as well as patients undergoing memory assessment with diagnosis of mild cognitive impairment (amyloid negative /amyloid positive) and diagnosis sporadic Alzheimer´s diases are recruited from Karolinska memory clinic and undergoing similar Multi-PET/MRI studies , fluid biomarker analysis, neuropsycholigal testing. The aim is to describe the evolution and spreading of tau in brain in Alzheimer continuum and compare with other pathological markers with aim of develop new diagnostic markers and therapeutic targets.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

a)belonging to families with known familial form of Alzheimer´s disease b) patient undergoing memory assessent at memory clinic with diagnosis mild cognitive impairment (MCI), Alzheimer´s disease c)healthy elderly cognitive normal

-

Exclusion criteria

cancer and other serious disease

Treatment and study plan

18F-RO948

Other

Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease

Primary outcomes

  1. PET measurement of regional tau spreading in brain during Alzheimer continuum

    Time frame: 3 years

    Anaysis of regional deposition of tau in brain

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Acronym: ROADAD

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Dec 12, 2024
Registry last updated
Dec 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.